Plasma biomarker reflecting cerebral amyloid deposition: a multicenter study for the clinical applicatio
Phase 2
Recruiting
- Conditions
- Alzheimer's disease Other Dementia Mild cognitive impairment (MCI) Healthy volunteer
- Registration Number
- JPRN-UMIN000023976
- Lead Sponsor
- ational Center for Geriatrics and Gerontology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
Having a risk for the MRI measurements, such as a heart pacemaker, implanted body metals, and a nerve stimulator. Having significant disease. A history of alcohol or drug addiction.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint of the study is to evaluate the ability of our plasma biomarkers to estimate the presence (or absence) of brain amyloid deposition, by referring the results of amyloid-PET imaging as the gold standard.
- Secondary Outcome Measures
Name Time Method 1) To test quantitative correlation between plasma biomarker values and brain amyloid deposition. 2) To evaluate the performances (e.g. sensitivity and specificity) of the biomarkers for each clinical category 3) Longitudinal changes between the changes in clinical symptoms and biomarker values.